Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

NCT05519085 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT05519085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05519085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Recruiting
Start date
September 20, 2022
Completion date
November 30, 2033
Enrollment
810 (estimated)
Sites
266

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma